...
首页> 外文期刊>Journal of pharmacological sciences. >Formyl peptide receptor 1 and 2 dual agonist inhibits human neutrophil chemotaxis by the induction of chemoattractant receptor cross-desensitization.
【24h】

Formyl peptide receptor 1 and 2 dual agonist inhibits human neutrophil chemotaxis by the induction of chemoattractant receptor cross-desensitization.

机译:甲酰基肽受体1和2双重激动剂通过诱导趋化性受体交叉脱敏作用抑制人嗜中性粒细胞的趋化性。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Formyl peptide receptor 1 (FPR1) and FPR2/ALX are known to control neutrophil chemotaxis in response to various ligands. In this study, we investigated the inhibitory mechanism of compound 43 (Cpd43), an FPR1 and FPR2/ALX dual agonist, on human neutrophil chemotaxis. Precedent stimulation of human peripheral blood neutrophils with Cpd43 rendered the cells unresponsive in calcium mobilization induced by interleukin-8, C5a, or leukotriene B. In addition, neutrophils pretreated with Cpd43 lost their chemotactic responses against these chemoattractants, wherein the expressions of chemoattractant receptors CXCR1, CXCR2, C5a receptor, and leukotriene B receptor 1 on the surface of neutrophils were all diminished significantly by treatment with Cpd43. By evaluating its pharmacological effect on 341 molecules, including receptors and enzymes, we also confirmed that Cpd43 has a highly specific affinity to FPR1 and FPR2/ALX and does not show binding affinity to the other chemoattractant receptors. These results indicate a previously unrecognized inhibitory mechanism of Cpd43 on neutrophil chemotaxis: the induction of cross-desensitization of multiple chemoattractant receptors in human neutrophils through its FPR1 and FPR2/ALX dual agonism.
机译:已知甲酰基肽受体1(FPR1)和FPR2 / ALX可响应各种配体来控制嗜中性粒细胞的趋化性。在这项研究中,我们研究了FPR1和FPR2 / ALX双重激动剂化合物43(Cpd43)对人嗜中性白细胞趋化性的抑制机制。用Cpd43刺激人类外周血中性粒细胞使细胞对白介素8,C5a或白三烯B诱导的钙动员无反应。此外,用Cpd43预处理的中性粒细胞失去了对这些趋化剂的趋化反应,其中趋化性受体CXCR1的表达中性粒细胞表面的CXCR2,C5a受体和白三烯B受体1均通过Cpd43处理而显着减少。通过评估其对包括受体和酶在内的341个分子的药理作用,我们还证实Cpd43对FPR1和FPR2 / ALX具有高度特异性,而对其他趋化因子受体没有结合亲和力。这些结果表明,Cpd43对嗜中性粒细胞趋化性的抑制机制尚未得到认可:通过其FPR1和FPR2 / ALX双重激动作用诱导人类嗜中性粒细胞中多种趋化因子受体的交叉脱敏。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号